Anavex Life Sciences Corp (AVXL)

[jimmy667]

Huge implications of A2-73PLUS Patent, Do not underestimate.

The patented legally distinct drug A2-73PLUS uses the lowest approved dose of Donepezil as part of its synergistic formula.

If A2-73PLUS performs as well as higher doses of Donepezil alone with less side effects it would meet critiria for approval.

There are over 30 generic forms of Donepezil approved by the FDA,by 30 manufactures from the likes of SANDOZ. TEVA, DrReady's and many smaller companies. One would assume that they are all at least marginally profitable. When/IF A2-73PLUS is approved it will likely capture a large part of that market due to lower side effects alone.

So ask yourselves does A2-73PLUS really have 97% chance of failure like the ABeta plaque and Tau tangle drugs?

Or would this high chance of failure be more correctly assigned to BIIB's plaque removal drug?